FindTrial
Sign In

Glycosylated hemoglobin is a predictive factor for response of radical radiotherapy in patients with stage 3 non-small cell lung cancer

Glycosylated hemoglobin is a predictive factor for response of radical radiotherapy in patients with stage 3 non-small cell lung cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0006199
Enrollment
100
Registered
2021-05-28
Start date
2021-04-24
Completion date
Unknown
Last updated
2021-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Kyung Hee University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Histologically confirmed primary lung cancer - From January 2010 to December 2019, the patients received radical radiotherapy in Kyung University Medical Center for management of lung cancer - AJCC stage 3 lung cancer - ECOG performance status 0, 1, or 2 - Follow-up period =1 year after completion of radiotherapy - The patients who were checked hemoglobin A1c 2 week before the start of radiotherapy

Exclusion criteria

Exclusion criteria: - Histologically confirmed small cell lung cancer - Receipt of a total radiotherapy dose =50 Gy - No available imaging studies for evaluation of cancer recurrence

Design outcomes

Primary

MeasureTime frame
Loco-regional recurrence-free survival rate—

Secondary

MeasureTime frame
Distant metastasis-free survival rate;Overall survival rate—

Countries

Korea, Republic of

Contacts

Public ContactMoonkyoo Kong

Kyung Hee University Hospital

kongmoonkyoo@khu.ac.kr+82-2-958-8661

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026